COMMUNIQUÉS West-GlobeNewswire

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/04/2024
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees [...]
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
16/04/2024
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder [...]
Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology
16/04/2024
Late breaking poster presentation includes Phase 1b clinical trial results demonstrating the safety and preliminary efficacy of KM-001, a topical TRPV3 inhibitor, for the treatment of palmoplantar keratoderma Oral [...]
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
16/04/2024
Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe atopic dermatitis [...]
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
16/04/2024
ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16/04/2024
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating [...]
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16/04/2024
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that [...]
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
16/04/2024
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern [...]
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
16/04/2024
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering [...]
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
16/04/2024
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare [...]
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
16/04/2024
Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy Patients [...]
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
16/04/2024
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05) [...]
Growth of 28% of 2024 first quarter revenue
16/04/2024
Press release Ecully, April 16, 2024 – 8 p.m. First-quarter 2024 revenue of €3.1 million Growth of 28% compared with 2023 first quarter In thousands of euros 2024 2023 Change 2023/2022 Q1 revenue 3,070 2,398 +28% [...]
Croissance de 28% du chiffre d'affaires du 1er trimestre 2024
16/04/2024
Communiqué de presse Ecully, le 16 avril 2024 –20h Chiffre d’affaires du 1 er trimestre 2024 de 3,1 M€ Progression des ventes de + 28% par rapport au 1 er trimestre 2023 En milliers d’euros 2024 2023 Variation en % CA 1 [...]
Pacific Health Care Organization, Inc. Reports its 2023 Year-End Financial Results
16/04/2024
Irvine, April 16, 2024 (GLOBE NEWSWIRE) -- Irvine, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission [...]
CARBIOS wins "So French So Innovative" award at InnoEX 2024, Hong Kong, recognizing French innovation in Asia Pacific
16/04/2024
CARBIOS wins "So French So Innovative" award at InnoEX 2024, Hong Kong, recognizing French innovation in Asia Pacific Clermont-Ferrand, France, Tuesday 16 April 2024 (6.30pm CET) CARBIOS (Euronext Growth Paris: ALCRB), [...]
CARBIOS remporte le prix « So French So Innovative » à l'occasion d’InnoEX 2024, Hong Kong, qui récompense l’innovation française dans la région Asie-Pacifique
16/04/2024
CARBIOS remporte le prix « So French So Innovative » à l'occasion d’InnoEX 2024, Hong Kong, qui récompense l’innovation française dans la région Asie-Pacifique Clermont-Ferrand (France), le mardi 16 avril 2024 (18h30 [...]
Brian Jones of AssureCare Honored with Outstanding Dietitian of the Year Award by Tennessee Academy of Nutrition and Dietetics
16/04/2024
CINCINNATI, April 16, 2024 (GLOBE NEWSWIRE) -- AssureCare , a leading provider of integrated population health management software and a prominent healthcare technology company, is delighted to announce that Brian Jones [...]
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
16/04/2024
COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2023 was adopted. The Board of Directors’ proposal to [...]

Pages